US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy
By Siddhi Mahatole
(Reuters) -Capricor Therapeutics said on Monday the U.S. Food and Drug Administration (FDA) plans to convene a panel of outside experts before deciding on the company's cell therapy for a heart condition related to Duchenne muscular dystrophy (DMD).
Shares of the drug developer fell nearly 15% to $10.11 in morning trade.
The company is seeking full approval for its experimental cell therapy, deramiocel, as a potential treatment for patients diagnosed with Duchenne muscular dystrophy cardiomyopathy.
"We believe today's share weakness is unwarranted," H.C. Wainwright analyst Joseph Pantginis said, adding the opportunity to present at the meeting is "likely to strengthen the therapy's petition".
The heart muscle disease is a leading cause of death among patients with DMD, a condition characterized by progressive skeletal and heart muscle weakness.
The FDA is set to decide on the therapy by August 31, although the official date for the advisory panel meeting is yet to be set.
The mass firings at the FDA under Health and Human Services Secretary Robert F. Kennedy Jr. have sparked concerns about potential delays in the drug review process.
However, the FDA Chief Martin Makary said last week there were no plans for major reorganization at the agency and that it will meet its targets for completing reviews of new drugs despite the layoffs.
In March, the company said that the FDA had not indicated whether an advisory committee would be necessary but said that it had been actively preparing for one.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Experts doubt FBI's claim that crop fungus smuggled by Chinese students is a threat
By Heather Schlitz CHICAGO (Reuters) -A biological sample that a Chinese researcher was accused of smuggling into the United States and that prosecutors cast as a "dangerous biological pathogen" is a common type of fungus already widespread in U.S. crop fields that likely poses little risk to food safety, experts said. On Tuesday, U.S. federal prosecutors accused two Chinese researchers of smuggling samples of the fungus Fusarium graminearum into the U.S., describing it as a potential agricultural terrorism weapon. Yunqing Jian, 33, a researcher at the University of Michigan's Department of Molecular, Cellular and Developmental Biology has been charged in connection with allegations that she helped her boyfriend, Zunyong Liu, 34, smuggle the pathogen into the U.S. However, agriculture experts interviewed by Reuters this week said the fungus has been in the U.S. for more than a century, can be prevented by spraying pesticides, and is only dangerous if ingested regularly and in large quantities. "As a weapon, it would be a pretty ineffective one," said Jessica Rutkoski, a crop sciences professor, wheat breeder and geneticist at the University of Illinois at Urbana-Champaign. Rutkoski and other researchers said extensive testing for the fungus' toxin, widespread use of fungicides and the difficulty of intentionally creating an infection with the pathogen would make it a clumsy weapon. The U.S. Attorney's Office and the FBI declined Reuters' request for comment. Since the 1900s, U.S. farmers have been battling the fungus, which causes Fusarium head blight, usually known as "scab," which often infects wheat, barley and other grains on farms during rainy years. The telltale pink streaks on the grain heads contain a toxic byproduct called vomitoxin, which is tested for and tightly controlled by grain elevators where farmers sell their crops. Constant testing and monitoring means that only negligible amounts of vomitoxin ever make it into the bread, pasta and cookies Americans eat, far below levels that would sicken a human, experts said. "We have a long history of managing epidemics of scab," said Andrew Friskop, professor and plant pathologist at North Dakota State University, noting that farmers have access to many tools to prevent and control the disease. Farmers began regularly spraying their fields with fungicide as early as the 1990s, and researchers have since developed multiple strains of fungus-resistant wheat. Plant experts said that it would be difficult to fully assess the risks posed by the samples without more information on the particular strain. But Rutkoski, whose research involves intentionally contaminating wheat with the fungus, said that she isn't always successful at infecting her test field's wheat with scab. She said the pathogen is difficult to control, and her lab has to strike the right balance of temperature and humidity to create an infection. In federal court in Detroit on Tuesday, Jian was charged with conspiracy to commit offense or to defraud the U.S., smuggling goods into the U.S., false statements and visa fraud. Jian did not comment on the charges, and the lawyer who represented her in court was not immediately available for comment. Liu could not be immediately reached for comment. The court scheduled Jian's bail hearing for June 13.
Yahoo
an hour ago
- Yahoo
HistoSonics completes pivotal histotripsy system trial enrolment
As reports of an acquisition by one of the leading players in the medical device space percolate, HistoSonics has completed enrolment in a pivotal trial to evaluate its histotripsy platform in treating kidney tumours. The US company's prospective, multi-centre, single-arm pivotal #HOPE4KIDNEY (NCT05820087) trial is designed to evaluate the effectiveness and safety of the Edison system for the destruction of kidney tissue by treating primary solid renal tumours. A total of 67 patients have been enrolled with a single, non-metastatic solid kidney mass ≤3cm. Patients will be treated with the Edison system and followed for five years post-procedure, with data at the 90-day evaluation point to be submitted in support of regulatory approval with the US Food and Drug Administration (FDA). The Edison system uses a technology called histotripsy, involving the delivery of non-thermal, non-invasive focused ultrasound waves to target and eliminate cancerous liver tissue. The system received de novo clearance from the US Food and Drug Administration (FDA) in 2023 and last month secured its first major insurance coverage from a new healthcare policy from Healthcare payor Blue Cross Blue Shield of Michigan (BCBSM) and health plan option Blue Care Network. HistoSonics' vision is for its Edison system to become a 'foundational, non-invasive' solution across a range of clinical applications, the company's CEO, Mike Blue stated. 'Completing enrolment in our pivotal kidney tumour trial represents a significant milestone toward that goal and reinforces our confidence in expanding histotripsy into additional tumour types and indications,' said Blue. In May, Edison histotripsy system has been granted controlled early limited market access in the UK under an Unmet Clinical Need Authorisation (UCNA) under the UK's Innovative Devices Access Pathway (IDAP), launched by the UK Government in 2023 to help fast-track 'transformative medical technologies' into the healthcare system. As first reported by the Financial Times last month, HistoSonics is seeking a valuation of more than $2.5bn for a takeover of the company, with Medtronic, GE HealthCare and Johnson & Johnson (J&J), a longtime backer of HistoSonics, among the interested parties evaluating the business. J&J most recently participated in HistoSonics' $102m Series D funding round. "HistoSonics completes pivotal histotripsy system trial enrolment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
2 hours ago
- CBS News
Acid spill at Cold Springs Pilgrim's plant sends 26 to hospital, police say
Minneapolis City Council calls for investigation into federal raid, and more headlines Minneapolis City Council calls for investigation into federal raid, and more headlines Minneapolis City Council calls for investigation into federal raid, and more headlines More than two dozen people were hospitalized after an acid spill at a chicken facility in central Minnesota Friday morning, police said. A peracetic acid spill occurred at the Pilgrim's facility on the 800 block of Sauk River Road in Cold Spring around 8:15 a.m., according to the city's police department. The spill was contained and the facility was evacuated. Twenty-six people were taken to a nearby hospital for evaluation. The U.S. Food and Drug Administration said peracetic acid is often used as a cleaning agent. In poultry facilities, it is often used "to reduce bacterial contamination and foot spoilage," the FDA said. The acid's concentrated form can cause "irreversible damage to skin and eyes," the FDA said, while the diluted forms can cause eye, nose, throat and respiratory irritation. The Pilgrim's facility recently underwent a $75 million expansion. Cold Spring is about 80 miles northwest of Minneapolis. This story will be updated.
